Company Filing History:
1 out of 3 
1 out of 5,450 
Years Active: 2023
Title: Max Rodnick-Smith: Innovator in Nicotine Degradation
Introduction
Max Rodnick-Smith is an accomplished inventor based in Austin, Texas. He has made significant contributions to the field of biotechnology, particularly in the development of nicotine-degrading enzyme variants. His work aims to address the challenges associated with nicotine degradation, which has implications for both environmental and health-related applications.
Latest Patents
Max Rodnick-Smith holds a patent for nicotine-degrading enzyme variants. This patent describes variants that exhibit increased nicotine-degrading activity and/or decreased immunogenicity compared to the wild-type NicA2 and NOX enzymes. The patent also includes compositions comprising these variants and methods for utilizing them effectively.
Career Highlights
Throughout his career, Max has worked with notable organizations, including Antidote Therapeutics, Inc. and the University of Texas System. His experience in these institutions has allowed him to collaborate with other experts in the field and contribute to innovative research.
Collaborations
Some of Max's coworkers include Matthew W. Kalnik and Thomas Thisted. Their collaborative efforts have further advanced the research and development of nicotine-degrading technologies.
Conclusion
Max Rodnick-Smith is a pioneering inventor whose work on nicotine-degrading enzyme variants showcases his commitment to innovation in biotechnology. His contributions have the potential to make a significant impact on both environmental sustainability and public health.